Matthew W. Davis, M.D., RPh joins the Aquestive team from Neuvivo, an ALS/neuroinflammation biotechnology company, where he served as Chief Medical Officer from August 2024 to November 2025. Prior to that, Dr. Davis held the offices of Chief Medical Officer and Chief Operating Officer at Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, from July 2022 through July 2024. Dr. Davis previously served as Chief Medical Officer of Endo Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on pain management, urology, endocrinology and aesthetics, from January 2017 through April 2022. Dr. Davis has over 27 years of pharmaceutical experience in various roles, including as Chief Medical Officer and Chief Scientific Officer, at various companies, including Lupin Pharmaceuticals, United Research Laboratories, and Dermik (Aventis). Dr. Davis earned his Medical Degree from Drexel University College of Medicine and undertook his General Surgery training at Brown University and his Urologic training at Washington Hospital Center. Dr. Davis also received a Bachelor of Science in Pharmacy degree from Temple University School of Pharmacy.